

STUDY TITLE	SALTO - A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged ≥ 2 to < 18 years with Pulmonary Arterial Hypertension
STUDY POPULATION	Pulmonary arterial hypertension (PAH) diagnosis confirmed by documented historical right heart catheterization (RHC) performed at any time before participant's screening and eligible based on the research inclusion and exclusion criteria.
PRINCIPAL INVESTIGATOR	Dr. Geetha Kandavello, Senior Consultant Paediatric Cardiologist, PCHC Cardiology Dept, IJNSB
STUDY COORDINATOR	Izzatun Nafsi Contact number : 03 – 2617 8200 Ext 3122
START DATE	22 December 2020
END DATE	31 December 2028